middle.news
Nexalis Launches First Human Trial of Inhaled CBD for Panic Disorder
11:42am on Wednesday 4th of March, 2026 AEDT
•
Healthcare
Read Story
Nexalis Launches First Human Trial of Inhaled CBD for Panic Disorder
11:42am on Wednesday 4th of March, 2026 AEDT
Key Points
Phase 1 trial underway with first participant recruited
Randomised, double-blind, placebo-controlled design in healthy volunteers
Inhaled CBD delivery for rapid systemic absorption
Study to assess pharmacokinetics, safety, and tolerability
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
NEXALIS THERAPEUTICS (ASX:NX1)
OPEN ARTICLE